Danny McBryan

418 total citations
7 papers, 311 citations indexed

About

Danny McBryan is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Infectious Diseases. According to data from OpenAlex, Danny McBryan has authored 7 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Physiology and 0 papers in Infectious Diseases. Recurrent topics in Danny McBryan's work include Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers), Asthma and respiratory diseases (7 papers) and Respiratory Support and Mechanisms (6 papers). Danny McBryan is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers), Asthma and respiratory diseases (7 papers) and Respiratory Support and Mechanisms (6 papers). Danny McBryan collaborates with scholars based in Switzerland, United Kingdom and United States. Danny McBryan's co-authors include David Lawrence, Marc Decramer, Ronald Dahl, David Young, Carlos Cézar Fritscher, Gilles Devouassoux, Muhammad Shoaib, Kenneth R. Chapman, Peter Frith and R. Cameron and has published in prestigious journals such as The Lancet Respiratory Medicine, Respiratory Medicine and International Journal of COPD.

In The Last Decade

Danny McBryan

7 papers receiving 289 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Danny McBryan Switzerland	6	300	231	8	7	7	7	311
R Abrahams United States	7	513 1.7×	424 1.8×	4 0.5×	23 3.3×	5 0.7×	23	529
Christie Arrasate United Kingdom	3	398 1.3×	307 1.3×	13 1.6×	9 1.3×		6	411
Ferran Chuecos Spain	9	295 1.0×	240 1.0×	10 1.3×	5 0.7×		20	324
Damon Jack United States	6	512 1.7×	470 2.0×	7 0.9×	19 2.7×		8	548
Piet J.G. Cornelissen Netherlands	7	317 1.1×	281 1.2×	4 0.5×	4 0.6×		8	335
Jan Verhaert Belgium	5	495 1.6×	413 1.8×	9 1.1×	19 2.7×		6	526
Ruby Birk United States	6	339 1.1×	258 1.1×	13 1.6×	6 0.9×	1 0.1×	14	349
Alberto de la Hoz Germany	10	225 0.8×	175 0.8×	3 0.4×	10 1.4×		31	247
Michelle Henley United States	8	594 2.0×	465 2.0×	4 0.5×	25 3.6×		14	614
Catherine Scott-Wilson United States	7	254 0.8×	214 0.9×		8 1.1×		9	266

Countries citing papers authored by Danny McBryan

Since Specialization

Citations

This map shows the geographic impact of Danny McBryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danny McBryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danny McBryan more than expected).

Fields of papers citing papers by Danny McBryan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danny McBryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danny McBryan. The network helps show where Danny McBryan may publish in the future.

Co-authorship network of co-authors of Danny McBryan

This figure shows the co-authorship network connecting the top 25 collaborators of Danny McBryan. A scholar is included among the top collaborators of Danny McBryan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danny McBryan. Danny McBryan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Vincken, Walter, Joseph Aumann, Hungta Chen, et al.. (2014). Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. International Journal of COPD. 9. 215–215. 63 indexed citations

2.

Decramer, Marc, Kenneth R. Chapman, Ronald Dahl, et al.. (2013). Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. The Lancet Respiratory Medicine. 1(7). 524–533. 194 indexed citations

3.

Mahler, Donald A., Roland Buhl, David Lawrence, & Danny McBryan. (2013). Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. Pulmonary Pharmacology & Therapeutics. 26(3). 348–355. 10 indexed citations

4.

Compton, C., Danny McBryan, Enrica Bucchioni, & Francesco Patalano. (2013). The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics. 26(5). 562–573. 17 indexed citations

5.

Decramer, Marc, Andrea Rossi, David Lawrence, & Danny McBryan. (2012). Indacaterol therapy in patients with COPD not receiving other maintenance treatment. Respiratory Medicine. 106(12). 1706–1714. 13 indexed citations

6.

Decramer, Marc, Ronald Dahl, Oliver Kornmann, et al.. (2012). Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respiratory Medicine. 107(2). 223–232. 13 indexed citations

7.

Donohue, James F., Thomas M. Siler, Edward Kerwin, et al.. (2012). Efficacy And Safety Of Indacaterol 75 µg Once Daily In Patients With Moderate-To-Severe COPD: Pooled Analysis Of Two Phase III Trials. A2258–A2258. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact